Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans.
about
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edemaEFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment.A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Ranibizumab for the treatment of degenerative ocular conditions.[Current therapeutic options in retinopathy of prematurity].Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMDRanibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.Critical appraisal of ranibizumab in the treatment of diabetic macular edema.Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurityTreatment for stage 4A retinopathy of prematurity: laser and/or ranibizumab.Assessment of Corneal Sensation, Innervation and Retinal Nerve Fiber Layer in Patients Treated with Multiple Intravitreal Ranibizumab InjectionsA Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy.Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study).6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome.Comparison of Perioperative Ranibizumab Injections for Diabetic Macular Edema in Patients Undergoing Cataract SurgeryPharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator.The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic SubjectsEffects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.An update on the pharmacotherapy of neovascular age-related macular degeneration.Drug delivery techniques for treating age-related macular degeneration.Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.Ranibizumab: a review of its use in myopic choroidal neovascularization.Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway.Current choice of treatments for neovascular AMD.The role of Aflibercept in the management of age-related macular degeneration.Oxidative stress protection by exogenous delivery of rhHsp70 chaperone to the retinal pigment epithelium (RPE), a possible therapeutic strategy against RPE degeneration.Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic AtrophyA model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab.Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration.Intravitreal low-dosage bevacizumab for retinopathy of prematurity.Clinical pharmacology of intravitreal anti-VEGF drugs.Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.
P2860
Q28292764-D826BA8C-EFAE-4DAA-918E-394DDDB8D526Q30490563-D14AB8DD-3E7B-47F0-9188-B5B67AE5FE6FQ30490738-02604C50-949E-4921-90DB-F29D690BF6F1Q33561241-BE06D372-9888-4086-B5B4-26616B227F30Q33740152-1FAABD04-7544-4D76-AF5A-8091205C4E9EQ33831237-A7284874-62B5-4C7C-A952-DD78154ECB2CQ34501395-FA5033DA-CF82-4044-B157-FC1DD62B97F3Q34608306-7CF8BCE7-E9AC-4C93-A94A-F5416F50C47CQ34711043-2FA4D59C-74A9-4A07-9ED8-3EA2E76DFDA7Q34803171-012F5F42-D1A5-4F71-9964-95312B04D6DDQ35194800-D4CFD726-B65B-425A-9388-9840CD1501E5Q35851949-ABF8AD19-C561-43E9-9151-986E98B4528DQ36096360-7E569A9B-55D8-4C21-B9EC-86A7B8873D73Q36249045-0816DB1C-2058-482E-B8B9-28C79FBDDB68Q36731129-CC97F6B4-2F16-4CC7-9394-6CDA74DECB72Q36752284-EA7873F6-153D-44A0-BFBD-3AB39621109CQ36858958-6A2098E3-8C17-4920-8613-4828C90DBAC7Q37132220-65FE73B9-F6C1-4D10-B1DF-D2433BEB958EQ37133086-7EDF20BC-382A-436D-83B7-7276CE8EB257Q37183169-D23A803A-E199-41B9-B090-B07A7D526EB5Q37363376-40697689-7909-4BB6-A808-31C08E684632Q37545245-50639A13-EB48-4684-8484-D2D5C1480348Q37600183-39C1CE56-E799-4D54-A1C9-A193A7A27F8EQ38094076-9E10434C-8FA4-4F24-AB19-88282329489DQ38096462-904F9A37-8D06-4B3E-A04B-A9F89BADA5D4Q38161953-A632DB74-22FB-4E06-B584-41736BBDEC6CQ38168825-C3564BAE-0A28-4B9D-9F43-C630D0282176Q38223928-887E22F4-2E7B-45C3-A667-8637D14BE762Q38261105-CB269550-499D-4B77-B317-506C7E8BF757Q38285319-BC23615D-E13C-4F0A-994D-4E88E007D48DQ38777050-0BCA932E-48D2-4E1A-BB3C-F691358246E8Q38974841-7FA4FBD0-AB2F-4C3E-A464-198ABAC2D2DCQ40358167-0DB9CAF4-831D-4BD7-BDA2-C7954EC768AAQ40957787-0699DD8E-6B77-48C2-AC82-8CBA59A431E2Q44195126-7D52DE96-523E-498A-84E0-D6BF0E95B41AQ45147023-42A83EBD-592D-4790-ADEE-3BFB4B71381AQ48109878-4ECBB37F-F9D7-4C92-A5E4-B892BCD65E05Q48267717-C9367003-F255-4331-80C1-BFDE46A6712FQ50124713-ADFC09F2-70F7-4259-B559-94F2D03F509CQ50853137-7D1B8576-C3FE-4CF9-AD3B-13B3A2531DEA
P2860
Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@en
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@nl
type
label
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@en
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@nl
prefLabel
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@en
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@nl
P50
P1476
Intraocular pharmacokinetics o ...... ravitreal injection in humans.
@en
P2093
Carsten H Meyer
P304
682-686.e2
P356
10.1016/J.AJO.2012.03.047
P407
P577
2012-07-19T00:00:00Z